Snowball logo
logo
1681

Consun Pharmaceutical Group

HK$14.49-HK$0.15ย  (1.02%)
Estimate
Beta
0.476
Growth
Revenue, YoY
29.13%
Net income, YoY
36.68%
FCF, YoY
144.19%
Forecast
P/E (FWD)
9.1
EPS (FWD)
1.597
Dividends
Dividend yield
5.24%
Annual payout
HK$0.76
Next ex. div date
March 8, 27
Payout
46.99%
Div.growth, 5y
28.47%
Dividend growth streak
4 y
Div.rating
About the company
Ticker
1681
ISIN
KYG2524A1031
Country
China
Sector (GICS)
Healthcare
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Frequently asked questions

What sector does Consun Pharmaceutical Group (1681) operate in?

Consun Pharmaceutical Group belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is Consun Pharmaceutical Group (1681) current stock price?

As of the latest data, Consun Pharmaceutical Group stock price is HK$14.49, with a previous close of HK$14.64. Consun Pharmaceutical Group lost -HK$0.15 in the last trading session, representing a -1.02% loss.

What is Consun Pharmaceutical Group (1681) current market capitalization?

Consun Pharmaceutical Group market cap is approximately 12.14 billion.

What is Consun Pharmaceutical Group (1681) EBITDA?

Consun Pharmaceutical Group EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 676.32 million.

Does Consun Pharmaceutical Group (1681) pay dividends?

Yes. Consun Pharmaceutical Group pays semiannual dividends with an annualized yield of 5.24% and an estimated annual payout of HK$0.76 per share.

When is the next ex-dividend date for Consun Pharmaceutical Group (1681)?

The next ex-dividend date is scheduled for March 08, 2027.

What is Consun Pharmaceutical Group (1681) beta (volatility) score?

Consun Pharmaceutical Group has a beta of 0.476, indicating lower volatility than the overall market.